Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
about
Review. The neurobiology of pathological gambling and drug addiction: an overview and new findingsParkinson's disease and primate research: past, present, and futureParkinson's disease gene therapy: success by design meets failure by efficacyStem cells in human neurodegenerative disorders--time for clinical translation?Neurotrophic factors as a therapeutic target for Parkinson's diseaseReduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy.Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.Behavioral phenotyping of mouse models of Parkinson's disease.Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms.Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation.Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.Transient elevation of adult hippocampal neurogenesis after dopamine depletion.Zhichan powder regulates nigrostriatal dopamine synthesis and metabolism in Parkinson's disease ratsSynergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine.Nicotine and Parkinson's disease: implications for therapy.Critical aspects of clinical trial design for novel cell and gene therapies.Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approachOutcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study.Stem cell-based therapy for Parkinson's disease.Advances in the delivery of treatments for Parkinson's disease.Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.Evaluation and management of the non-motor features of Parkinson's disease.Parkinson's disease: the genetics of a heterogeneous disorder.Cell therapy for Parkinson's disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease.Nicotinic receptors as CNS targets for Parkinson's diseaseAlternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson's Disease with Dementia and Dementia with Lewy Bodies.Striatal shape in Parkinson's disease.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics.Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trialFive-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease.Single photon-emission computed tomography imaging in early Parkinson's disease.WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?
P2860
Q24641954-AFE87827-7B48-4492-80E5-36526841509AQ24655590-C653CC9F-C0CE-48CD-AB4F-EB340A208696Q26851325-F77DB87F-6C40-48AF-BF43-54D49D0BB10DQ27687068-9BA08DCD-3CC9-46EC-B6B5-1AC642EE42BAQ28273071-DEBF9E71-E62D-4C06-9722-3CB78D2A6A6BQ30439165-69467F83-98C8-4AAB-984D-011BA8F74272Q30496234-6C227381-EE26-4674-8D55-F9E1E0D1D446Q33820609-E57F291F-1E09-45F8-9D8C-84C8E27B8CF6Q34178488-E8D12C8B-F4F5-4EA9-B1C6-C49ED6831008Q34234632-EB0640E5-C62A-4321-8392-44BEDEF87259Q34306751-71F7A577-45FF-4575-A2C7-0124E0E703D1Q34459138-CED9D075-576C-45EC-AE99-9728A5C861FBQ34553777-4C634BAB-2D50-4D19-8605-57BB93220003Q34589616-A4E7C5AA-1D1C-4CBA-9118-047802537486Q34798682-DCBC395B-CB62-4711-9FE6-6614E79E183BQ34976266-BD58BAD7-50F7-47D2-9564-AE8FA98625AFQ35601652-EB77729F-67F9-462B-829B-6AF132D5D98DQ35664438-9671C769-DBEA-4FDA-AF54-913953B686F1Q35671348-D7A2A256-1790-4A6D-811B-FFE470E5A653Q36106907-6E9D9B16-C7B7-4AED-A2EA-A51E4987D1DCQ36227173-59648BD1-3E51-401B-9ED3-DDDAB23AA1CEQ36309562-0B1B2CC4-9CA1-454B-82DE-2923EEAAF9D3Q36316936-246F68FA-4770-46F8-A6E9-A04475EC4F5FQ36434541-880BA936-B551-48A7-A487-66825E86E310Q36443721-F19AD4CD-9C8C-4F75-B764-5BEF5AA6D202Q36516918-383E500A-31DF-47CE-83F1-66513022236AQ36660994-F40B6096-A83E-4FCA-8966-AA3767C754D4Q36882136-8FB3278E-EAA7-4CCA-8363-28BC0D12487DQ36913723-C508585C-B827-4306-B2EA-49259C083DBFQ36948446-C9C59D87-236E-4FB4-BAC1-F45A28C3BDA4Q37053738-E8A11EF2-286F-43AD-B27E-0C6C92EF0D8BQ37093252-1CEA7877-FC94-4399-BED3-0D82F373B9F5Q37098986-01E83A53-D431-4635-A18E-AF5ADD5A0988Q37214469-8A571412-40DE-496D-88DA-47AA56E27055Q37217333-52BCC0C8-96E8-49C1-8491-609848FF9CB6Q37327990-F3B3E8AE-4D6F-498D-95DC-F244AAE06E46Q37352055-8A603754-BE2B-4968-AC01-DA54F7D5C603Q37371387-23135989-6CC3-4FD8-85CF-E094288E032EQ37506492-3FD08202-2EAB-46FF-ACC8-18640EA000F9Q37506507-43ED46BB-F9CD-44D1-B525-FE976460EAAA
P2860
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Challenges in Parkinson's dise ...... dopamine system is not enough.
@ast
Challenges in Parkinson's dise ...... dopamine system is not enough.
@en
type
label
Challenges in Parkinson's dise ...... dopamine system is not enough.
@ast
Challenges in Parkinson's dise ...... dopamine system is not enough.
@en
prefLabel
Challenges in Parkinson's dise ...... dopamine system is not enough.
@ast
Challenges in Parkinson's dise ...... dopamine system is not enough.
@en
P1433
P1476
Challenges in Parkinson's dise ...... dopamine system is not enough.
@en
P2093
Jose A Obeso
P304
P356
10.1016/S1474-4422(04)00740-9
P50
P577
2004-05-01T00:00:00Z